EP4735480A1 - Anticorps multi-spécifiques comprenant des domaines de liaison à l'antigène reconnaissant de manière spécifique c5ar1 et gm-csfr alpha - Google Patents

Anticorps multi-spécifiques comprenant des domaines de liaison à l'antigène reconnaissant de manière spécifique c5ar1 et gm-csfr alpha

Info

Publication number
EP4735480A1
EP4735480A1 EP24830855.3A EP24830855A EP4735480A1 EP 4735480 A1 EP4735480 A1 EP 4735480A1 EP 24830855 A EP24830855 A EP 24830855A EP 4735480 A1 EP4735480 A1 EP 4735480A1
Authority
EP
European Patent Office
Prior art keywords
seq
amino acid
acid sequence
variant
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24830855.3A
Other languages
German (de)
English (en)
Inventor
Chong HE
Wenwu Zhai
Zhiwen Zhou
Michael George Strainic
Ping Yuan
Zuoan YI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Staidson Beijing Biopharmaceutical Co Ltd
Original Assignee
Staidson Beijing Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Staidson Beijing Biopharmaceutical Co Ltd filed Critical Staidson Beijing Biopharmaceutical Co Ltd
Publication of EP4735480A1 publication Critical patent/EP4735480A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps multispécifiques (par exemple, bispécifiques) qui reconnaissent de manière spécifique C5aR1 et GM-CSFRα, et des compositions pharmaceutiques comprenant des anticorps multispécifiques (par exemple, bispécifiques) qui reconnaissent de manière spécifique C5aR1 et GM-CSFRα. L'invention concerne également des procédés de fabrication et d'utilisation de ces anticorps.
EP24830855.3A 2023-06-27 2024-06-27 Anticorps multi-spécifiques comprenant des domaines de liaison à l'antigène reconnaissant de manière spécifique c5ar1 et gm-csfr alpha Pending EP4735480A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023102813 2023-06-27
PCT/CN2024/101864 WO2025002221A1 (fr) 2023-06-27 2024-06-27 Anticorps multi-spécifiques comprenant des domaines de liaison à l'antigène reconnaissant de manière spécifique c5ar1 et gm-csfr alpha

Publications (1)

Publication Number Publication Date
EP4735480A1 true EP4735480A1 (fr) 2026-05-06

Family

ID=93937692

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24830855.3A Pending EP4735480A1 (fr) 2023-06-27 2024-06-27 Anticorps multi-spécifiques comprenant des domaines de liaison à l'antigène reconnaissant de manière spécifique c5ar1 et gm-csfr alpha

Country Status (3)

Country Link
EP (1) EP4735480A1 (fr)
CN (1) CN121816363A (fr)
WO (1) WO2025002221A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020048A2 (fr) * 1995-11-30 1997-06-05 Bristol-Myers Squibb Company Molecules sfv modifiees mediatrices de l'adhesion entre cellules, et leurs utilisations
EP1739078A1 (fr) * 2005-05-30 2007-01-03 Jerini AG Antagonistes du recepteur C5a
CN116003597A (zh) * 2018-11-27 2023-04-25 舒泰神（北京）生物制药股份有限公司 特异性识别粒细胞-巨噬细胞集落刺激因子受体α的抗体及其用途
TWI869528B (zh) * 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN115925918A (zh) * 2021-07-06 2023-04-07 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用
CN118829654A (zh) * 2021-12-29 2024-10-22 舒泰神(加州)生物科技有限公司 特异性识别C5aR1的抗体及其应用

Also Published As

Publication number Publication date
CN121816363A (zh) 2026-04-07
WO2025002221A1 (fr) 2025-01-02

Similar Documents

Publication Publication Date Title
WO2022052974A1 (fr) Anticorps reconnaissant de manière spécifique le récepteur alpha de l'interleukine 4 et leurs utilisations
WO2022166739A1 (fr) Anticorps reconnaissant spécifiquement la lymphopoïétine stromale thymique et leurs utilisations
US20260015423A1 (en) Antibodies specifically recognizing programmed cell death1 ligand 1 and uses thereof
AU2019388584B2 (en) Antibodies specifically recognizing Granulocyte-Macrophage Colony Stimulating Factor Receptor alpha and uses thereof
WO2023129870A2 (fr) Anticorps reconnaissant spécifiquement c5ar1 et utilisations associées
WO2021259160A1 (fr) Anticorps reconnaissant de manière spécifique c5a et leurs utilisations
WO2023016538A1 (fr) Anticorps reconnaissant spécifiquement fcrn et leurs utilisations
US20250101120A1 (en) Antibodies specifically recognizing fasl and uses thereof
CN118812719A (zh) 特异性结合HBV pre-S1抗原和CD3抗原的多特异性抗体及其应用
JP7693806B2 (ja) シュードモナス属ｐｃｒｖおよびｐｓｌを特異的に認識する抗原結合を含む抗体の組み合わせ及び二重特異性抗体
WO2025002221A1 (fr) Anticorps multi-spécifiques comprenant des domaines de liaison à l'antigène reconnaissant de manière spécifique c5ar1 et gm-csfr alpha
CN117203230A (zh) 特异性识别c5a的抗体及其应用
EP4524158A1 (fr) Anticorps reconnaissant de manière spécifique gdf15 et son utilisation
EP4606886A1 (fr) Combinaison d'anticorps se liant spécifiquement à trail ou fasl, et anticorps bispécifique
EP4725501A1 (fr) Anticorps se liant de manière spécifique à masp3, et anticorps multispécifique se liant de manière spécifique à masp3 et masp2
WO2025195443A1 (fr) Anticorps multi-spécifique se liant de manière spécifique à light et à c5a, composition et utilisation associées
WO2025190332A1 (fr) Anticorps multi-spécifique se liant de manière spécifique à l'antigène nkg2a et à l'antigène pd-l1, et utilisation d'un anticorps multi-spécifique
CN120699159A (zh) 特异性结合LIGHT和GM-CSFRα的多特异性抗体以及组合物及其应用
CN120682370A (zh) 特异性结合LIGHT和IL-4Rα的多特异性抗体以及组合物及其应用
EA048006B1 (ru) Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения
EA049281B1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИ РАСПОЗНАЮЩИЕ PcrV PSEUDOMONAS, И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE